Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Total Non-Current Liabilities (2020 - 2025)

Cytek Biosciences' Total Non-Current Liabilities history spans 6 years, with the latest figure at $117.5 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 15.87% year-over-year to $117.5 million; the TTM value through Dec 2025 reached $117.5 million, up 15.87%, while the annual FY2025 figure was $117.5 million, 15.87% up from the prior year.
  • Total Non-Current Liabilities reached $117.5 million in Q4 2025 per CTKB's latest filing, up from $113.8 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $117.5 million in Q4 2025 to a low of $46.2 million in Q2 2021.
  • Average Total Non-Current Liabilities over 5 years is $90.7 million, with a median of $98.8 million recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: soared 73.86% in 2022, then dropped 6.1% in 2024.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $56.7 million in 2021, then surged by 62.82% to $92.3 million in 2022, then grew by 7.17% to $99.0 million in 2023, then rose by 2.46% to $101.4 million in 2024, then rose by 15.87% to $117.5 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Total Non-Current Liabilities are $117.5 million (Q4 2025), $113.8 million (Q3 2025), and $113.3 million (Q2 2025).